Panagora Asset Management Inc. Makes New $2.75 Million Investment in Phreesia, Inc. $PHR

Key Points

• Panagora Asset Management Inc. has acquired a new position in Phreesia, Inc., purchasing 107,418 shares valued at approximately $2.746 million, representing 0.18% ownership.
• Analysts are generally optimistic about Phreesia, with multiple firms issuing "buy" ratings and a consensus average price target of $32.58.
• Recent insider trading indicates a 15.78% and 11.28% decrease in ownership for two directors who sold a total of 119,874 shares valued at approximately $3.59 million over the last three months.

Panagora Asset Management Inc. bought a new stake in Phreesia, Inc. (NYSE:PHR - Free Report) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm bought 107,418 shares of the company's stock, valued at approximately $2,746,000. Panagora Asset Management Inc. owned approximately 0.18% of Phreesia as of its most recent filing with the SEC.

Other large investors have also recently modified their holdings of the company. Raymond James Financial Inc. bought a new position in shares of Phreesia in the 4th quarter valued at $379,000. First Trust Advisors LP boosted its holdings in shares of Phreesia by 306.9% during the 4th quarter. First Trust Advisors LP now owns 82,068 shares of the company's stock valued at $2,065,000 after acquiring an additional 61,898 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Phreesia by 1,023.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,660 shares of the company's stock valued at $142,000 after acquiring an additional 5,156 shares in the last quarter. Hsbc Holdings PLC boosted its holdings in shares of Phreesia by 36.5% during the 4th quarter. Hsbc Holdings PLC now owns 13,064 shares of the company's stock valued at $333,000 after acquiring an additional 3,493 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of Phreesia by 6.6% during the 4th quarter. Northern Trust Corp now owns 571,807 shares of the company's stock valued at $14,387,000 after acquiring an additional 35,392 shares in the last quarter. Institutional investors and hedge funds own 92.10% of the company's stock.

Insider Transactions at Phreesia

In other news, Director Mark Douglas Smith sold 7,000 shares of Phreesia stock in a transaction dated Wednesday, July 2nd. The stock was sold at an average price of $29.00, for a total value of $203,000.00. Following the completion of the transaction, the director directly owned 37,353 shares of the company's stock, valued at approximately $1,083,237. This trade represents a 15.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Michael Weintraub sold 7,431 shares of Phreesia stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $27.51, for a total value of $204,426.81. Following the completion of the transaction, the director directly owned 143,039 shares of the company's stock, valued at approximately $3,935,002.89. This trade represents a 4.94% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 119,874 shares of company stock worth $3,587,618. Corporate insiders own 5.50% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Stephens reissued an "overweight" rating and set a $32.00 price objective on shares of Phreesia in a report on Wednesday. Truist Financial raised their price objective on Phreesia from $34.00 to $35.00 and gave the company a "buy" rating in a report on Thursday, May 29th. Citigroup reissued a "buy" rating on shares of Phreesia in a report on Wednesday, May 28th. Canaccord Genuity Group raised their price objective on Phreesia from $34.00 to $38.00 and gave the company a "buy" rating in a report on Friday. Finally, KeyCorp raised their target price on Phreesia from $28.00 to $35.00 and gave the stock an "overweight" rating in a research report on Monday, July 14th. Thirteen analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Phreesia currently has an average rating of "Buy" and a consensus target price of $33.31.

Phreesia Trading Down 10.0%

Shares of PHR stock traded down $3.12 during mid-day trading on Friday, hitting $28.09. The company's stock had a trading volume of 2,671,573 shares, compared to its average volume of 819,069. The company's fifty day simple moving average is $28.34 and its 200-day simple moving average is $26.53. Phreesia, Inc. has a 52 week low of $17.07 and a 52 week high of $32.76. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.95 and a current ratio of 1.95. The company has a market cap of $1.67 billion, a PE ratio of -66.88 and a beta of 0.72.

Phreesia (NYSE:PHR - Get Free Report) last posted its quarterly earnings data on Thursday, September 4th. The company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.08. Phreesia had a negative return on equity of 9.00% and a negative net margin of 5.35%.The firm had revenue of $117.26 million during the quarter, compared to analyst estimates of $116.39 million. During the same period last year, the company posted ($0.03) EPS. The business's quarterly revenue was up 14.9% on a year-over-year basis. Phreesia has set its FY 2026 guidance at EPS. As a group, equities research analysts expect that Phreesia, Inc. will post -1.1 earnings per share for the current fiscal year.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.